This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Abiomed Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

5.2%

Tasa de crecimiento de los beneficios

4.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	4.3%
Tasa de crecimiento de los ingresos	12.3%
Rentabilidad financiera	17.3%
Margen neto	24.8%
Última actualización de beneficios	30 Sep 2022

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Abiomed. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:AIO Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 22	1,074	267	452	175
30 Jun 22	1,056	218	438	171
31 Mar 22	1,032	137	423	164
31 Dec 21	1,003	133	413	153
30 Sep 21	974	149	392	143
30 Jun 21	935	154	368	131
31 Mar 21	848	226	333	119
31 Dec 20	813	200	318	114
30 Sep 20	803	208	317	107
30 Jun 20	798	159	324	101
31 Mar 20	841	203	342	99
31 Dec 19	841	245	339	99
30 Sep 19	820	221	334	98
30 Jun 19	797	258	326	96
31 Mar 19	769	259	322	94
31 Dec 18	737	222	316	89
30 Sep 18	690	190	302	82
30 Jun 18	641	165	283	79
31 Mar 18	594	112	263	74
31 Dec 17	544	90	247	68
30 Sep 17	505	92	235	67
30 Jun 17	475	77	228	66
31 Mar 17	445	52	218	65
31 Dec 16	415	48	203	64
30 Sep 16	386	43	191	61
30 Jun 16	359	42	178	54
31 Mar 16	330	38	164	49
31 Dec 15	303	126	152	44

Ingresos de calidad: AIO has a large one-off gain of $61.8M impacting its September 30 2022 financial results.

Margen de beneficios creciente: AIO's current net profit margins (24.8%) are higher than last year (15.3%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: AIO's earnings have grown by 5.2% per year over the past 5 years.

Acelerando crecimiento: AIO's earnings growth over the past year (78.9%) exceeds its 5-year average (5.2% per year).

Beneficios vs. Industria: AIO earnings growth over the past year (78.9%) exceeded the Medical Equipment industry -37.2%.

This company listing is no longer active

Abiomed Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2023 earnings released: EPS: US$2.34 (vs US$1.25 in 2Q 2022)

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

First quarter 2023 earnings released: EPS: US$1.20 (vs US$0.58 loss in 1Q 2022)

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Recent updates

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Second quarter 2023 earnings released: EPS: US$2.34 (vs US$1.25 in 2Q 2022)

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings released: EPS: US$1.20 (vs US$0.58 loss in 1Q 2022)

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold €1.0m worth of stock

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

Abiomed, Inc. (NasdaqGS:ABMD) acquired all the assets and business from Sensera, Inc. for $7.5 million on January 4, 2022.

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold €4.5m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed Appoints of Myron L. Rolle to its Board of Directors

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

Revenue beats expectations

New 90-day high: €310

Abiomed, Inc. to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: €267

New 90-day low: €216

Second quarter 2021 earnings released: EPS US$1.38

Revenue beats expectations

Abiomed Announces FDA Grants 510(k) Clearance for the Company's Innovative Cardiopulmonary Support Technology

Abiomed, Inc. Announces New Protect Iii Study Data That Demonstrates Reduced Rates of MACCE

Abiomed, Inc. to Report Q2, 2021 Results on Oct 29, 2020

Abiomed, Inc. Not to Provide Earnings Guidance for the Fiscal Year 2021

New 90-day high - €263

Abiomed, Inc. (NasdaqGS:ABMD) acquired the remaining stake in Breethe, Inc.

Abiomed, Inc. to Report Q1, 2021 Results on Aug 06, 2020

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta